

SERIOUS ADVERSE EVENT REPORTING FORM

Initial Reporting: Once you have become aware of a SAE or SUSAR, please email this form to the BAMI Trial Office (BTO) [e-mail: bami@qmul.ac.uk] within 24 hours of learning of the event. "SAE report" must be in the email's subject line. The form should be signed by the Pl/delegated doctor, scanned and e-mailed to the BTO. If that could not be achieved, a signed copy of the same form (without editing and additional information) must be sent to the BTO at the earliest opportunity by fax [+44 20 3465 6491]. Once this form is received by the BTO an acknowledgment email will be sent to your site during office hours. If you do not receive an acknowledgement on the following working day, please contact the BTO [Tel: +44 20 3765 87401.

Full title of the study	The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (MN-MNC) on all cause-mortality in acute myocardial infarction		
Study Acronym	BAMI		
Name of sponsor	Queen Mary University of London		
Sponsor R&D Number	EudraCT Number: 2012-001495-11		
MREC Number	13/LO/0315		
Chief Investigator	Name: Prof Anthony Mathur		
	Phone No: (+44) 20 3765 8715		
	Email address: a.mathur@qmul.ac.uk		
Is this a double blind study?	No		
Name of IMP	T2c001 (Bone marrow derived mononuclear cells (BM-MNCs))		

The following sections should be completed by the SITE:				
Report type:				
Subject identification code:	Patient/initials (first, last):			
	stephen, hawking			
Date of Birth: (Day/Month/Year)	Patient's Age:	Sex:		
23 /11 /1941	76	⊠ M □ F		
Principal Investigator				
Name:	Phone No:	Email address:		
piyush	7895432176			
Trial Co-ordinator at local site:				
Name:	Phone No:	Email address:		
shark				
Reporting host institution				
Trust/ Institution name:		Site number:		
shark Blood testing institute		49		
Date of site become aware of event:	Onset date of SAE:	Resolution date of SAE:		
22 /10 /2006	23 /10 /2006	01 /02 /2007		
Event description (eg. body site, symptoms): Please use separate form for each event patient is suffering from Spinal cord and nerve root disorders which is of type Sacral radiculopathy.				





Type of SAE	Severity		
□ Results in Death	Mild		
	☐ Moderate		
Hospitalisation or prolongation of hospitalisation	Severe Severe		
Persistent or significant disability or incapacity			
Congenital anomaly or birth defect			
"Other" important medical event			
If "Other", please describe:			
Bone marrow derived mononuclear cells re-in	fusion		
Was IMP (t2c001) infused?	Re-infusion Date: Re -Infusion Time:		
⊠ Yes □ No	27 /12 /2006 15 : 00 24 hour clock		
Causal relationship to IMP Is the SAE likely to be related to the IMP	Causal relationship to intervention		
t2c001?	Does the SAE have a causal relationship to the intervention?		
□ Unrelated	⊠ Bone Marrow Aspiration		
	☐ Cardiac Catheterisation		
⊠Patient in control arm	Not related to invasive procedure		
	No intervention taken		
Is the SAE expected? (Expected reactions will be found in the Investigator Brochure and protocol)	Is the SAE due to the progression of an underlying illness?		
	⊠ Yes □ No		
Is the event classified as a SUSAR? (i.e. RELATED to the IMP and UNEXPECTED)	Is the SAE related to the trial CONDUCT?		
If Yes, please give IMP batch number			
T2c001 Batch Number: 234642			
*If regarded as SUSAR, please also fill in the CIOMS form attached to this form			
Names of non IMPs concomitant medicines:	Names of concomitant diseases:		
EXERMET-500mg	Sacral radiculopathy		
	<u></u>		
If SAE during index admission, action taken with study treatment	Did the PI withdraw the patient from the study?		
☐ Infused	⊠ Yes		
☐ Not Infused	□ No		
☐ Infusion interrupted			
☐ Not applicable, please Give details:			



Outcome of SAE					
Resolved					
Resolved with sequelae	*Date of death: 14 /03 /2018				
*specify sequelae:	*Copy of post-morte	m available? ☐ Yes			
☐ Improved		⊠ No			
Persisting					
∀ Worsened ✓ Worsened	│				
Worsened	Officiowif				
Additional information requested by the Cl's team for this project:					
Relevant Medical History :	Relevant Lab Results / Imaging Results (e.g. ECG, blood test):				
	blood test: nueron scanning				
Delegated person completing the form if not the					
Print name:	Phone No.:	Email address:			
stephen hawking	8765432189				
Signature:	Job title:	Date:			
	software engineer				
Principle Investigator / Delegated person	[Email address:			
Print name:	Phone No.:	Email address.			
george					
Signature:	Date:				
For BAMI Trial Office use only					
Date form RECEIVED by BAMI Trial Office from	Reviewed by:				
Investigator Site:					
13 /11 /2007	Date reviewed: 22 /12 /2007				
(This date will be DAY 1 for SUSARs)					
Chief investigator reviewed	Fully Assessment Director				
Date: / /	Fully Agree with PI's assessment				
	☐ Yes ⊠No				
Cl's signature:	If No, please specify worst PI assessment ever				
	WOIST LI GOSESSIIIEHT EAGL				
For R&D Office use only					
Date form RECEIVED by R&D team:	For SUSAR only				
1 1	Date Reported to MHRA:				
Reviewed by:	12 /11 /2007				
Date reviewed: / /					

